NCT00202540终止2 期
Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- Episodic memory
研究概览
简要总结
The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Memory complaint
- •Acetylcholinesterase inhibitors stopped at least 3 months before selection
排除标准
- •Parkinson's disease
- •Vascular disorder
- •Depression
结局指标
主要结局
Episodic memory
次要结局
- Other cognitive domains, activities of daily living, global impression of change, MRI, safety.
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period.An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.EUCTR2004-004327-35-GBInstitut de Recherches Internationales Servier450
进行中（未招募）
不适用
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period.An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.EUCTR2004-004327-35-DEInstitut de Recherches Internationales Servier450
进行中（未招募）
不适用
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period.An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.Mild Cognitive ImpairmentMedDRA version: 5.1Level: PTClassification code 10027175EUCTR2004-004327-35-BEInstitut de Recherches Internationales Servier450
终止
2 期
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's DiseaseAlzheimer's DiseaseNCT00602680Sanofi1
已完成
2 期
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's DiseaseAlzheimer's DiseaseNCT01009255GlaxoSmithKline196